Chinese firm Belief BioMed launches $350K hemophilia B gene therapy, challenging $3.5M Hemgenix by CSL Behring/uniQure, as China leads global race for cheaper gene therapies.

EveryOne Medicines, a biotech developing individualized genetic therapies, to close after FDA's new guidance falls short of expectations for streamlined drug approvals.

EveryOne Medicines, a biotech developing individualized genetic therapies, to close after FDA's new guidance falls short of expectations for streamlined drug approvals.

Swiss-based life sciences company Swiss Rockets will buy MGI subsidiary Complete Genomics, the companies said Monday. Terms of the deal were not disclosed.

After mounting a comeback with fresh capital and a flashy partnership, cancer testing firm Grail once again faces major questions over the future of its blood test that screens for dozens of cancers.

NeuExcell Therapeutics says it slowed an aggressive form of cancer in the first human test of a gene therapy technique that aims to coax the brain into healing itself.

With a valuation of about $61.2 billion, Hengrui is now larger than Takeda and Bayer. But there’s still one big item on its bucket list: selling its own treatments outside of China.

Former Intellia scientist John Finn reflects on gene editing's evolution and the closure of Tome Biosciences, highlighting the industry's focus on tools over medicines.

HHS Secretary Robert F. Kennedy Jr. added metachromatic leukodystrophy and Duchenne to a federal newborn screening list, reviving efforts that had been stalled under the Trump administration — though ...

IITs have grown increasingly popular among China researchers over the past decade, and have helped China’s fast-growing biotech sector catch up with rivals in the US and Europe. The very leniency that...

A recurring roundup of news about former KSJ Fellows, including a compendium of what the fellows have been writing.

Nationwide Children's Hospital delivers first gene therapy for SLC6A1 disorder to 8-year-old Maxwell Freed, showing early promise in treating seizures and developmental delays.

Analysis: Chinese biotech dominates ESMO cancer conference with 3 major studies, including Kelun's Sac-TMT ADC showing 40% reduced death risk, sparking debate on FDA's stance on China-only data.

Grail’s blood test got better at telling when a positive result actually means cancer based on study findings, potentially strengthening the company’s case for a wider rollout, though questions remain...

Listening to the news can feel like a journey. But 1A guides you beyond the headlines – and cuts through the noise. Let's get to the heart of the story, together – on 1A.Support NPR and get your news ...

D’Angelo, the Grammy-winning R&B singer recognized by his raspy yet smooth voice and for garnering mainstream attention with the shirtless “Untitled (How Does It Feel)” music video, has died.

Indian veterinarian Nirnay Murthy sought Lantu Biopharma's experimental gene therapy for his son's spinal muscular atrophy after being unable to afford Novartis's $2.1M Zolgensma treatment.

Indian veterinarian Nirnay Murthy sought Lantu Biopharma's experimental gene therapy for his son's spinal muscular atrophy after being unable to afford Novartis's $2.1M Zolgensma treatment.

Indian veterinarian Nirnay Murthy sought Lantu Biopharma's experimental gene therapy for his son's spinal muscular atrophy after being unable to afford Novartis's $2.1M Zolgensma treatment.

Some of the studies that underpin the Trump administration’s decision to veer away from mRNA vaccine research are being misapplied, co-authors of the work say, muddling the move by HHS and Secretary R...

Roche revealed the latest cut of data from its closely-watched Phase 1/2 study of trontinemab, an amyloid-targeting antibody designed to latch onto receptors that yank it across the protective blood-b...

FDA to request Sarepta halt shipments of DMD drug Elevidys after two patient deaths, HHS official says. Trading of $SRPT shares paused after decline.

Patient dies from liver failure in Sarepta Therapeutics' gene therapy trial for limb-girdle muscular dystrophy, following two deaths in company's Elevidys DMD program.

atient groups face a harder and unpredictable path going state-by-state to boost screening for rare but treatable conditions after the Trump administration disbanded a federal advisory committee on ne...

atient groups face a harder and unpredictable path going state-by-state to boost screening for rare but treatable conditions after the Trump administration disbanded a federal advisory committee on ne...

US investors debate response to China's rise in drug development, with some seeing a national security threat while others embrace collaboration. FDA and policymakers consider reforms to maintain comp...

US investors debate response to China's rise in drug development, with some seeing a national security threat while others embrace collaboration. FDA and policymakers consider reforms to maintain comp...

FDA Commissioner Marty Makary reportedly attempted to reject KalVista Pharmaceuticals' drug application, sources said. An HHS spokesperson calls the claim 'totally false.'

Illumina to acquire proteomics company SomaLogic for $350M upfront from Standard BioTools, expanding beyond DNA sequencing into protein analysis technology.

Neuroscientist, biologist and 2021 Nobel Prize winner Ardem Patapoutian joined Midday Edition to talk about how the Trump administration's effort to cut back on science spending is impacting researche...

In 2020, Jaci Hermstad died at age 26 from a rare and aggressive form of ALS. But her story didn’t end there.

For Illumina, its former employees are both a boon and a problem. In the 27 years since its founding, the DNA sequencing company unlocked new frontiers in biology, medicine and ...

For Illumina, its former employees are both a boon and a problem. In the 27 years since its founding, the DNA sequencing company unlocked new frontiers in biology, medicine and ...

Biotech companies face financial strain from expensive long-term leases signed during pandemic boom, with Ginkgo Bioworks, Prime Medicine & others struggling with high lease obligations amid market do...

Empower Pharmacy has used poor-quality ingredients, skirted regulations and pushed out or sued employees who raised concerns, an Endpoints News investigation found.

Recognizing excellence in writing for a specialized audience

Recognizing excellence in writing for a specialized audience

Illumina on Thursday said the SEC has closed its investigation into the company's $8 billion purchase of Grail and doesn't intend to pursue enforcement action, confirming Endpoints News' reporting ear...

Fyodor Urnov and Kiran Musunuru advocate for streamlined CRISPR treatments for rare genetic diseases, partnering with Danaher and CHOP to develop custom therapies for HLH and metabolic disorders.

The SEC is expected to drop an investigation into Illumina's $8 billion acquisition of cancer test developer Grail, Endpoints News has learned.

President Trump met with pharma CEOs at the White House. After praising investments, a 'most favored nation' drug pricing plan has sparked industry alarm.

The SEC is expected to drop an investigation into Illumina's $8 billion acquisition of cancer test developer Grail, Endpoints News has learned.